Dr. Jain on Hematopoietic Recovery Following CAR T-Cell Therapy
Tania Jain, MBBS, discusses hematopoietic recovering following treatment with a chimeric antigen receptor T-cell therapy in patients with hematologic malignancies.
Tania Jain, MBBS, assistant professor at Johns Hopkins University, discusses hematopoietic recovering following treatment with a chimeric antigen receptor (CAR) T-cell therapy in patients with hematologic malignancies.
The most important thing to know, regarding this type of treatment, is that patients can remain cytopenic for a long time following CAR T-cell therapy. In some patients, they can remain cytopenic for months after receiving treatment, says Jain. The need for transfusions and risk for infections needs to be recognized.
Currently, there are no standard guidelines in terms of how long a patient should receive antimicrobial prophylaxis; this remains to be determined so it can prevent infections for a longer period of time in patients.
